Welcome to our dedicated page for Biomx SEC filings (Ticker: PHGE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BiomX Inc. (PHGE) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including Form 8-K current reports and other key documents filed with the U.S. Securities and Exchange Commission. These filings offer detailed information on BiomX’s clinical-stage phage therapy programs, corporate actions and financing arrangements, and they complement the company’s press releases for investors researching PHGE stock.
BiomX’s recent Form 8-K filings describe several material events. These include the initiation and terms of a private placement of Series Y Convertible Preferred Stock and related warrants, with details on dividend rights, conversion mechanics, exercise prices, registration rights and stockholder approval requirements. Other 8-Ks outline the authorization and implementation of a one-for-nineteen reverse stock split of the common stock listed on NYSE American under the symbol PHGE, along with proportional adjustments to equity awards, warrants and convertible preferred stock.
Filings also document significant developments in BiomX’s clinical and operational landscape. The company has reported an FDA clinical hold on the U.S. portion of its BX004 Phase 2b study, subsequent FDA follow-up questions on a third-party nebulizer device, and the eventual discontinuation of the BX004 Phase 2b trial after internal review and Data Monitoring Committee recommendations. Additional 8-Ks describe cost-cutting measures, workforce reductions, and the decision by the board of BiomX Ltd., an Israeli subsidiary, to approve and authorize the filing of an application to commence insolvency proceedings. Lease termination terms for Adaptive Phage Therapeutics, LLC, a wholly owned subsidiary, are also set out in detail.
Through this page, users can review how BiomX reports on its BX011 and BX211 phage programs for diabetic foot disease, its capital structure changes, and board and governance matters. Stock Titan enhances these filings with AI-powered summaries that highlight key terms, clinical implications and capital market impacts, helping readers quickly understand complex items such as preferred stock designations, warrant adjustments, clinical trial disclosures and strategic alternatives discussed in BiomX’s SEC reports.
BiomX Inc. entered into an amendment to a previously issued warrant covering up to 3,300,000 shares of common stock that were issued with 3,300 shares of Series Y Convertible Preferred Stock sold in December 2025. The amendment shortens the warrant’s term so it now expires on December 31, 2026, reduces the exercise price from $2.00 to $1.00 per share, and changes the cashless exercise formula to reference the lowest VWAP over the five trading days before exercise notice. The number of underlying warrant shares remains unchanged. In a CEO letter, BiomX describes this as part of a broader financial and strategic reset aimed at simplifying its capital structure, resolving long-dated warrant overhang, cutting costs including closing a Maryland facility, and exploring a pivot toward sectors such as advanced technologies and defense-related applications.
BiomX Inc. director and 10% owner Yeganeh Reuven, through Pyu Pyu Capital LLC, converted Series Y Convertible Preferred Stock into Common Stock at a conversion price of $2.00 per share and then sold the resulting shares in private transactions.
Pyu Pyu Capital LLC received 450,000 and 530,000 Common shares upon conversion and sold all 980,000 shares at $5.00 per share in private deals. It also sold 5,000,000 Common Stock Purchase Warrants in private transactions at prices between $4.76 and $5.24 per warrant share, leaving no Common Stock or warrants reported as held after these transactions.
BiomX Inc. director and 10% owner Yeganeh Reuven, through Pyu Pyu Capital LLC, reported a series of conversions and sales of the company’s stock. Pyu Pyu converted Series Y Convertible Preferred Stock into a total of 670,000 shares of Common Stock at $2.00 per share, then sold those 670,000 Common shares in private transactions at $5.00 per share over March 11–13, 2026. The filing notes the securities are directly owned by Pyu Pyu Capital LLC and may be deemed beneficially owned by Reuven as its sole member, with Reuven disclaiming beneficial ownership except to the extent of his pecuniary interest.
BiomX Inc. reported the final results of a special stockholder meeting held on March 11, 2026. As of the February 3, 2026 record date, 1,593,516 shares of common stock were outstanding and all 1,593,516 votes were represented in person or by proxy.
Stockholders approved two proposals described in the company’s February 13, 2026 proxy statement. One proposal received 528,511 votes for, 23,714 against, and 4,753 abstentions. The other received 524,578 votes for, 31,778 against, and 622 abstentions. No further adjournment of the meeting was required.
BiomX Inc. reported significant leadership changes. On March 4, 2026, Jonathan Solomon resigned from the board, all board committees, and his roles as Chief Executive Officer and Chief Principal Officer, effective immediately. The company states his resignation did not result from any disagreement over operations, policies, or practices.
On the same date, Chairman of the Board Dr. Russell Greig resigned from the board and its committees, also without any stated disagreement. The board appointed Amir Shalom as a Class I director, deemed independent under NYSE American rules, with his term expiring at the 2027 annual meeting, and he will receive standard director compensation and an indemnification agreement.
To fill the CEO vacancy, the board appointed Michael Oster as Chief Executive Officer effective March 4, 2026, noting his extensive experience in strategy, M&A, and operational leadership. As of this report, no compensatory arrangement with Mr. Oster has been entered into. Effective March 5, 2026, the board also reassigned members and chairs of its Audit, Compensation, and Nominating and Corporate Governance Committees.
BiomX Inc. director Bidas Liat Cohavi has filed a Form 3, which is an initial statement of insider status at the company. The data provided shows no buy, sell, acquisition, or disposition transactions, only that Cohavi is currently serving as a director.
BiomX Inc. reported significant leadership changes and a delayed shareholder vote. On February 24, 2026, its Chief Financial Officer and Chief Development Officer resigned, and on February 25, 2026, three directors resigned from the Board and all committees. The company stated that none of these resignations involved any disagreement over operations, policies, or practices.
On February 27, 2026, the Board appointed David Rokach as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, citing his executive, governance and investment experience. Separately, a Special Meeting of Stockholders convened on February 25, 2026 was adjourned due to lack of quorum and is expected to reconvene on March 11, 2026, with the record date remaining February 3, 2026 and no changes to the proposals.
BiomX Inc. reported changes to its Board of Directors. On February 19, 2026, Alan Moses resigned from the Board for personal reasons and indicated he had no disagreements with the company regarding its operations, policies, or practices.
On February 25, 2026, the Board appointed Guy Arieli as a Class I director with a term expiring at the 2027 annual meeting and Shaked Ran as a Class III director with a term expiring at the 2026 annual meeting, filling two existing vacancies. Both are experienced investment and pension advisory professionals, were deemed independent under NYSE American rules, and will receive standard director compensation with prorated annual cash fees. The company will enter into indemnification agreements with each on substantially the same terms as for its other directors.
BiomX Inc. is a clinical-stage company developing bacteriophage therapies targeting harmful bacteria in chronic conditions such as diabetic foot infections and osteomyelitis. The company has no approved products and has never generated revenue from product sales.
In December 2025 BiomX discontinued development of its cystic fibrosis candidate BX004 after adverse events and resource constraints, and later began insolvency proceedings for its Israeli subsidiary BiomX Ltd., which previously housed core operations. A court-appointed trustee now controls that subsidiary, and BiomX no longer treats it as an asset.
To address severe liquidity pressure, BiomX entered a Securities Purchase Agreement for 3,300 shares of Series Y Convertible Preferred Stock and warrants, for $3.0 million in gross proceeds. If stockholders approve the deal, the investor is expected to become the majority common stockholder and could change the company’s business, strategy and objectives. The company’s risk factors highlight substantial doubt about its ability to continue as a going concern and emphasize that its future depends heavily on securing this stockholder approval and further financing.
Alyeska Investment Group and related reporting persons filed an amended Schedule 13G showing beneficial ownership of 38,176 shares of BiomX Inc. common stock, representing 2.5% of the class. This amount includes 1 share of common stock and warrants to purchase 38,175 additional shares.
The ownership percentage is based on 1,526,640 BiomX common shares outstanding, after a 19:1 reverse stock split reported in a prior Form 8-K. The filers certify the position is held in the ordinary course of business and not for changing or influencing control of BiomX.